<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Induced-Pluripotent-Stem-Cells-Ipsc on Bioecon</title><link>https://en.bioecon.ru/technologies/induced-pluripotent-stem-cells-ipsc/</link><description>Recent content in Induced-Pluripotent-Stem-Cells-Ipsc on Bioecon</description><generator>Hugo</generator><language>en-US</language><lastBuildDate>Sat, 19 Sep 2026 01:21:58 +0700</lastBuildDate><atom:link href="https://en.bioecon.ru/technologies/induced-pluripotent-stem-cells-ipsc/index.xml" rel="self" type="application/rss+xml"/><item><title>Induced pluripotent stem cells (iPSC)</title><link>https://en.bioecon.ru/technology/induced-pluripotent-stem-cells-ipsc/</link><pubDate>Fri, 18 Sep 2026 18:05:00 +0000</pubDate><guid>https://en.bioecon.ru/technology/induced-pluripotent-stem-cells-ipsc/</guid><description>Reprogramming adult cells into an embryonic-like, expandable stem state — the platform behind off-the-shelf NK cells, defined culture media and human-iPSC developmental toxicology. Three ledger-backed rows; the therapy and autoimmune applications belong to sibling pages.</description></item></channel></rss>